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Abstract: Due to constant antigenic drift and shift, current influenza-A vaccines need to be redesigned
and administered annually. A universal flu vaccine (UFV) that provides long-lasting protection against
both seasonal and emerging pandemic influenza strains is thus urgently needed. The hemagglutinin
(HA) stem antigen is a promising target for such a vaccine as it contains neutralizing epitopes,
known to induce cross-protective IgG responses against a wide variety of influenza subtypes. In this
study, we describe the development of a UFV candidate consisting of a HAstem trimer displayed on
the surface of rigid capsid-like particles (CLP). Compared to soluble unconjugated HAstem trimer,
the CLP-HAstem particles induced a more potent, long-lasting immune response and were able to
protect mice against both homologous and heterologous H1N1 influenza challenge, even after a
single dose.
Keywords: universal influenza vaccine; HA-stem antigen; capsid-like particles; Virus-like particles;
trimer display; IgG2a; pandemic preparedness
1. Introduction
Influenza A is a respiratory virus causing up to 5 million cases of severe illness and between 290,000
and 650,000 influenza-related deaths every year [1]. Current influenza vaccines are directed against
the major surface antigens, hemagglutinin (HA) and neuraminidase (NA). These vaccines generate
strain-specific responses and therefore need to be re-designed annually in response to antigenic shift
and drift [2,3]. This cumbersome process is further complicated by the current production methods,
which are largely still reliant on traditional egg-based propagation. This process is slow, costly and
severely restricts the number of doses that can be produced for a given flu season, meaning we are left
largely unprepared for pandemic outbreaks [4–7]. Consequently, several alternative approaches are
being pursued with the aim to develop a universal flu vaccine (UFV), ideally offering life-long protection
against a broad range of viral strains and subtypes including emerging pandemic strains [8,9].
The HA protein is responsible for the recognition and entry of the virus into target cells
and is integral to its infectivity. In the native confirmation, HA is a homotrimeric membrane
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glycoprotein composed of a hypervariable head and a more conserved stem region. Although
the human immune system can react against both regions, most of the response is directed towards
the variable head. In the context of developing a UFV, one promising strategy to increase the
breadth of protection is to focus the immune response towards the more conserved HA-stem. This
region is known to contain epitopes for broadly neutralizing antibodies (bnAb) and several HA-stem
antigens have proven to elicit cross-protective antibody responses in preclinical animal models [10–16].
In addition to direct neutralization of the virus, antibodies directed against the stem region mediate
a number of Fc-R-dependant functions including phagocytosis and antibody-dependent cellular
cytotoxicity (ADCC), which contributes significantly to the overall protection [17–19]. Importantly,
high concentrations of HA-stem-specific antibodies are required for adequate immunity. Therefore, the
low intrinsic immunogenicity of the HA-stem region [20] and the fact that current HA-stem antigen
designs contain immune-dominant, non-neutralizing epitopes (including neo-epitopes formed during
their engineering) pose a significant challenge to the development of an HA-stem-based UFV. Therefore,
optimal vaccine formulation of the HA-stem antigen is essential to maximize immunogenicity,
engage both adaptive and innate immune functions, and favour display of bnAb epitopes over
non-neutralizing epitopes.
On that basis, we investigated whether the immune response towards a HA-stem vaccine candidate
that has previously shown to elicit bnAb responses in both mice and non-human primates [11], could
be improved by presenting it on the surface of rigid capsid-like particles (CLP). Due to their size and
repetitive surface geometry, which mimic that of live viruses, CLPs induce rapid lymph node drainage,
enhanced innate immune activation and strong B-cell receptor cross-linking, leading to potent and
long-lasting antibody responses [21,22]. In this study, CLP-display of HAstem was achieved using the
Tag/Catcher-AP205 vaccine platform [23–26]. Upon mixing of the antigen and CLP components, stable
antigen:CLP complexes are formed by the spontaneous formation of isopeptide bonds between the
reactive tag (SpyTag) and Catcher protein (SpyCatcher), which are genetically fused to the antigen
and CLP subunit protein, respectively. Accordingly, the platform can facilitate unidirectional and
high density display of even large and complex proteins [26] and has previously been demonstrated
to increase immunogenicity and mediate a focused antibody response targeting specific parts of the
displayed antigen [27].
Our results show that CLP-display of the trimeric HAstem protein modified the isotype profile of
the induced antibodies and significantly improved the protective capacity of vaccine-induced responses
in mice challenged with both homologous and heterologous H1N1 influenza strains.
2. Materials and Methods
2.1. Design, Expression and Purification of HAstem Trimer Antigen
The HAstem antigen was engineered by Impagliazzo et al. based on the H1N1 A/Brisbane/59/2007
sequence [11]. To enable CLP-display, the HAstem sequence #4900 [11] was genetically fused at the
C-terminus with a 6xhistidine tag followed by a Glycin-Glycin linker and the Spytag sequence
(AHIVMVDAYKPTK) (Figure S1). The gene sequence was further modified to contain a BamHI
restriction site at the N-terminus and a stop-codon followed by an EcoRI restriction site at the
C-terminus. The codon optimized (Trichoplusia ni cells) gene sequence was finally synthesized by
Geneart (Life Technologies).
To generate recombinant HA-stem influenza trimers, flashBAC™ Gold DNA (Oxford Expression
Technologies, Oxford, UK) was co-transfected with pAcGP67A/HAstem into Sf9 insect cells using
Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA, USA), according to manufactures instructions.
Supernatant containing recombinant Baculovirus was harvested and used to generate a high-titer virus
stock, for infection of High-Five insect cells. Infected High-Five cells were incubated for 16–28 h at
28 ◦C with shaking. The filtered supernatant was buffer exchanged (1 × PBS, pH 7.4, supplemented
with 60 mM Imidazole) and concentrated using a QuixStand Benchtop system (10,000 MWCO hollow
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fiber cartridge, surface area 650 cm2 (GE Healthcare, Chicargo, IL, USA) followed by filtration through
a 0.22 µm filter. The 6xhistidine tagged recombinant HA-stem protein was purified on a 5 mL HisTrap
HP column (GE healthcare). Bound protein was eluted with 500 mM Imidazole in 1 × PBS buffer,
pH 7.4. To isolate assembled HAstem trimers, HAstem protein fractions were further purified by
size-exclusion chromatography using a Highload Superdex 200 pg chromatography column (GE
healthcare). Fractions containing HAstem trimers were identified by non-reducing SDS-PAGE. Protein
concentrations were measured using a BCA kit (Thermo Fisher Scientific, Waltham, MA, USA).
2.2. Expression and Purification of CLP Platform, SpyCatcher-AP205
The expression and purification of SpyCatcher-CLP has previously been described [23]. Briefly,
SpyCatcher was genetically fused to the N-terminus of the bacteriophage AP205 coat protein (Gene
ID: 956335). The SpyCatcher-CLP gene sequence was cloned in a pET-15b vector, using NcoI and
NotI restriction sites, and recombinant expression was performed in E. coli One Shot® BL21 Star™
(DE3) cells (Invitrogen). Purification of SpyCathcer-CLP was performed by ultracentrifugation over an
Optiprep™ (Sigma-Aldrich, St Lois, MO, USA) density step gradient.
2.3. Conjugation of HAstem Trimer to CLP Platform
To develop CLP-HAstem, SpyTagged HAstem trimers and SpyCatcher-CLP were mixed in a 1:1
molar ratio and incubated overnight at 4 ◦C. Unbound excess HA-stem antigen was removed by
density step-gradient ultracentrifugation. The CLP-HAstem was finally dialyzed against a 1xPBS buffer,
pH 7.4, using a 1000 kDa MWCO dialysis tube (Spectrum Labs, San Francisco, CA, USA).
2.4. Quality Assessment of the HAstem CLP Vaccine
The CLP-HAstem vaccine was assessed via Dynamic Light Scattering (DLS) as described
previously [28]. In brief, the vaccine was spun at 15,000 g for 10 min, before being loaded into
a Eppendorf Uvette cuvette (Sigma-Aldrich, St Louis, MO, USA) and measured 20 times at 25 ◦C on a
DynoPro NanoStar (WYATT Technology, Santa Barbara, CA, USA) using a 658 nm laser. Dynamics
software, Version 7.5.0 (WYATT Technology, Sanata Barbara, CA, USA) was used to estimate the
intensity-average diameter (nm) and percentage polydispersity (%Pd). CLP-HAstem was further
visualized by negative stain Electron Microscopy as described in the subsequent section.
2.5. Negative-Stain Electron Microscopy Sample Preparation, Data Collection, and Processing
HAstem trimers were mixed with MEDI8852 Fab fragments at a molar ratio of 1:3 HA trimer to
Fab fragment for 1 h at room temperature. Complexed HAstem:MEDI8852 samples and CLP-HAstem
samples were diluted to 0.01 mg/mL with 1× TBS, and then 3 µL of sample was immediately applied
to glow-discharged 400 mesh carbon-coated Cu grids. Grids were subsequently stained with 2%
(wt/vol) uranyl formate for 35–45 s and then blotted using filter paper until completely dry. All grids
were imaged on a 120 kV FEI Tecnai Spirit electron microscope (FEI, Hillsboro, OR, USA) using a
nominal magnification of ×52,000, resulting in 2.05 Å/px. Micrographs were collected using a TVIPS
TemCam-F416 (4 k × 4 k) camera with the Leginon interface [29] and a defocus of 1.5 µm. Particles
were selected using a Difference of Gaussians (DoG) picker in Appion [30], extracted, and classified
into 2D class averages with Relion v2.1 [31].
2.6. Bio-Layer Interferometry
CR9114 and S9-3-37 IgG at 5 µg/mL or MEDI8852, C05, and HIV PG9 Fab fragments at 20 µg/mL
were loaded onto anti-human IgG Fc Capture (AHC) or anti-human Fab CH1 (FAB2G) biosensors
(ForteBio, Fremont, CA, USA) in kinetics buffer (0.01% BSA + 0.002% Tween20 in 1× phosphate-buffered
saline) and dipped into wells containing HAstem (135 nM or 270 nM), CLP-HAstem (250 nM or 500 nM
total protein), or kinetics buffer alone using an Octet Red96 instrument (ForteBio). After loading,
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association was measured for 700 s, followed by dissociation for 750 s in kinetics buffer. A baseline
containing kinetics buffer was subtracted from each data set, and curves were aligned on the y axis
using the baseline step.
2.7. Animal Immunization Studies
Female Balb/cA mice, 6–8 weeks old, were obtained from Janvier Labs and housed in a specific
pathogen–free facility. Before being used in experiments, animals were allowed to acclimatized at the
facility for at least 1 week.
Endotoxins were removed from CLP-HAstem vaccine formulations as previously described [32],
and formulated with AddaVaxTM (InvivoGen, San Diego, CA, USA) according to the manufacturer’s
instructions. Mice were immunized intramuscularly with either CLP-HAstem or with a vaccine
formulation containing soluble HAstem trimers. An antigen dose-escalation study was conducted by
vaccinating mice with 1, 5 or 10 µg HAstem (soluble or CLP displayed) following prime-boost-boost
regimen with a 3-week interval. Influenza virus challenge was performed 1 month after the last
boost using the heterologous strain A/Puerto Rico/8/1934 (H1N1/PR8). For the longevity-study, mice
were vaccinated every 3rd week with 4.5 µg HAstem (CLP display vs. soluble) in a prime-boost-boost
setting and challenged 35 weeks after the first immunization with the homologous influenza strain
H1N1A/Brisbane/59/2007 (H1N1/Brisbane). Finally, for the one-shot study, mice were vaccinated
once with 4.5 µg HAstem (CLP display vs. soluble) and 1 month after the final vaccination mice were
challenge with PR8 or Brisbane strain.
2.8. Serum Immunoglobulin Levels
To assess the vaccine-induced antibody responses, enzyme-linked immunosorbent assay (ELISA)
was used to measure HAstem-specific antibody levels, as previously described [23]. In brief, 96-well
microtiter plates (Nunc MaxiSorp, Inivtrogen) were coated with 0.1 µg/well recombinant HAstem
protein, which was then incubated with a serial dilution of serum. Plates were probed with the relevant
HRP-conjugated secondary antibody (i.e., anti-mouse IgG/IgG1/IgG2a/IgG3) and then developed with
a tetramethylbenzidine (TMB) substrate and the absorbance subsequently measured at OD 450 nm.
For the longevity study, the geometric means of the titers (GMT) were calculated on all bleeds. For all
other studies, the endpoint titers are reported and unless otherwise stated in the figure, a cut off of OD
0.1 was applied.
2.9. Virus Challenge
The influenza viruses H1N1 Brisbane A/59/07 (Brisbane) and H1N1 A/Puerto Rico/8/34 (PR8)
were used for sub-lethal challenge studies as described previously [33,34]. An amino acid sequence
comparison of the HAstem protein between the two viral strains can be seen in Figure S1b. For
each virus preparation, the lethal dose was determined, and 1–3 LD50 used. For Brisbane challenge,
this corresponded to 100,000 PFU and for PR8 challenge 100 PFU was used. Mice were anaesthetized
using an i.p. injection of 250 mg/kg avertin (2,2,2 tribromoethanol in 2-methyl-2-butanol), and then
infected i.n. with 30 µL of appropriately diluted influenza virus. Following influenza challenge, mice
were assessed by daily weights.
2.10. Influenza Virus Plaque Assay
Three or five days post influenza challenge, mice were euthanized and the lungs harvested and
frozen via cryopreservation. Lungs were homogenized using sterilized sand and a mortar and pistil.
PBS + 1% FBS was added to the samples to obtain a 10% weight/volume suspension and then spun for
15 min at 600 G and 4 ◦C. Supernatant was collected and kept on ice until use.
MDCK plaque assay was performed as previously described [33]. Briefly, 4.5 × 104 MDCK cells
were grown in 96-well plates overnight in 100 µL complete medium. Ten-fold dilutions of the lung
suspensions were prepared using an influenza growth medium containing DMEM 1965 medium with
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0.2% BSA, 2 mM L-glutamin, 200 IU/mL penicillin, 50 µg/mL streptomycin, 1% sodium-pyruvate,
and 5 units/mL TPCK Trypsin. MDCK-cells were washed twice with PBS and then incubated with
50 µL of each virus dilution for 2 h at 37 ◦C, 5% CO2. Media was then removed, and the cells were
overlayed in a medium containing 2× minimum essential medium (MEM) eagle supplemented with
0.4% BSA, 10% NaHCO3, 2% Streptomycin, 2% penicillin and 5 units/mL TPCK trypsin mixed 1:1 with
1.8% methylcellulose. Following a 48 h incubation at 37 ◦C and 5% CO2, the overlay was removed
and the wells were washed twice with PBS. Cells were fixated with 4% formaldehyde for 30 min at
room temperature and then washed twice with PBS and permeabilised with warm 0.5% Triton-X in
Hanks balanced salt solution medium. Cells were subsequently washed and then incubated with
primary α-influenza nucleocapsid A mAb (Nordic Biosite, Copenhagen, Denmark) diluted 1:1500
in PBS + 1% BSA for 1 h at 37 ◦C and 5% CO2. The antibody was removed and cells washed five
times. This was followed by incubation with a goat α-mouse HRP conjugated secondary mAb (Dako,
Glostrup, Denmark) at a 1:500 dilution in PBS + 1% BSA for 1 h at 37 ◦C, 5% CO2. Cells were
subsequently washed five times with PBS before adding 200 µL substrate solution containing 3 mg/mL
3-amino-9-ethylcarbazole, 0.07% H2O2 and 5 mM citrate phosphate buffer (pH 5) to the wells for
30 min at room temperature. The substrate was removed and cells were washed before counting.
All samples were run in duplicates. Plaque forming units per g lung tissue was calculated according to
the following formula:
Dilution factor × average number of plaques/well × 20 = PFU/g
Detection level was calculated to be 500 PFU/g (2.7 log PFU/g)
2.11. Ethical Statement
All animal experiments were approved by the Danish Animal Experiments Inspectorate, approval
numbers: 2018-15-0201-01541 and 2015-15-0201-00623, and were conducted in accordance with national
Danish guidelines. Mice were housed in an AAALAC accredited facility in accordance with good
animal practice as defined by FELASA.
2.12. Statistical Analysis
To determine statistical significance of ELISA endpoint titers and the plaque assays, pairwise
comparisons of immunization groups was performed using an unadjusted, non-parametric, two-tailed,
Mann–Whitney Rank Sum Test, with a statistical significance defined at p < 0.05.
3. Results
3.1. Development and Characterization of a CLP Vaccine Displaying a Trimeric HAstem Protein
A previously described HAstem protein, based on A/Brisbane/59/2007 (H1N1) influenza virus [11],
was genetically modified to contain a C-terminal SpyTag and subsequently expressed and purified from
baculovirus-transfected insect cells. The Spytagged HAstem formed stable disulfide-linked trimers,
similar to the original HAstem protein (Figure 1a and Figure S2a). To further characterize the protein,
the presence and accessibility of known bnAb epitopes was confirmed by Bio-layer interferometry
using MEDI8852 [35], CR9114 [36] and S9-3-37 [37] monoclonal antibodies (Figure 1b and Figure S3).
Electron microscopy of HAstem- MEDI8852 complexes revealed that three Fab molecules bound to each
trimer (Figure 1b). These analyses demonstrated that well-characterized bnAb epitopes were retained
in the SpyTag-modified HAstem recombinant protein, and that the protein shares a similar structure
with the native HA surface antigen. Mixing of Spytagged HAstem trimers with SpyCatcher-CLP
resulted in the formation of HAstem CLPs, each displaying approximately 20–30 HAstem trimers
per particle (Figure 1c,d). Excess unconjugated HAstem antigen could efficiently be removed by
ultracentrifugation (Figure 1d and Figure S2b). Interestingly, the majority of HAstem trimers were
anchored to the CLP using multiple (i.e., two or three) of the Spytags present at the C-terminus of
each protomer. This was evidenced by the small percentage of surface displayed HAstem protomers
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that was not covalently bound to a CLP subunit (Figure 1d lane 3). Dynamic light-scattering (DLS)
analysis and transmission electron microscopy revealed that HAstem CLPs were largely monomodal
and monodispersed (polydispersity of 14.3%) and had a larger diameter (58 nm) than the unconjugated
SpyCatcher-CLP (46 nm) (Figure 1e and Figure S2e). The CLP-HAstem contained bacterial RNA, which
is encapsulated during its assembly inside the bacterial production cell (Figure S2c,d). All vaccine
formulations had low endotoxin levels (<3 EU/mL). Bio-layer interferometry analysis of the CLP-HAstem
particles showed that high-density display of the trimers did not compromise the accessibility of
known broadly neutralizing epitopes (Figure S3). Together, these results suggested that the Tag/Catcher
AP205 system could be used to display the HAstem antigen in a CLP structural format, allowing further
comparative studies (CLP-HAstem versus soluble HAstem) to assess the potential benefits of multivalent
CLP antigen display.
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Figure 1. Design and characterization of CLP-HAstem vaccine displaying known broadly neutralizing
epitopes. (a) Structure of the HAstem trimer, based on HA from A/California/04/2009 H1N1 (PDB ID
4M4Y). Amino acids corresponding to the head region of HA have been removed and epitopes of
the bnAb’s MEDI8852, CR9114 and S9-3-37 are colo red r d. (b) Representative 2D class averages
of HAstem trimer in complex with MEDI8852 Fab imaged using negative-stain EM. For one such
image, 2D class densities attributed to the Fab are coloured red. (c) CLP-HAstem vaccine development
process. The stem region of a monomeric H1 hemagglutinin (HA) (genetically fused to Spytag at the
C-terminus) was recombinantly expressed. The SpyCatcher-CLP and HAstem trimer were expressed
and purified separately and subsequently mixed. The tag/catc er covalent conjugatio system ensures
a vaccine with HAstem trimers presented unidirectionally and at high density on the CLP. (d) Reduced
SDS-PAGE analysis showing the coupling of the CLP (lane 1) to the HAstem antigen, resulting in a band
shift comprising of one CLP capsid unit covalently bound to one HAstem (lane 2). After conjugation,
excess uncoupled antigen was removed by density ultracentrifugation (lane 3). M = molecular weight
marker. (e) Representative negative stain electron microscopy of CLP-HAstem vaccine, showing uniform,
non-aggregated particles of approximately 58 nm in diameter. Scale bar represents 200 nm length.
3.2. Increased Immunogenicity of CLP-HAstem Offers Potential Dose Sparring
The immunogenicity and protective capacity f the CLP-HAstem particles wa compared
head-to-head with a similar vaccine formulation containing soluble HAstem trimer. In a dose-escalation
study, mice were immunized with a prime, boost, boost regime, and vaccine-induced anti-HAstem
antibody levels were measured 2 weeks after each vaccination (Figure 2a). After the first immunization
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(measured at week 2), all mice vaccinated with CLP-HAstem had a high antibody response, which
was not affected by the antigen dose. In comparison, mice receiving soluble HAstem protein produced
significantly lower antibody responses (p < 0.005) and 6 out of the 10 mice receiving the lowest
dose failed to generate a detectable anti-HAstem titer (Figure 2b). The second vaccination with the
CLP-HAstem vaccine (measured at week 5) led to a 2-log increase in ELISA antibody titers, again
irrespective of the antigen dose, and this level of anti-HAstem antibodies did not increase substantially
after the third vaccination (measured at week 8). In comparison, only mice that received the highest
dose of soluble HAstem antigen produced a similarly high level of anti-HAstem antibodies after the
second vaccination, whereas antibody levels in mice receiving lower doses (1 µg and 5 µg) needed three
immunizations to reach this titer (Figure 2b). Serum from naïve mice showed no reactivity against the
HAstem trimer (data not shown).
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Figure 2. Dose-response study showing increased i unogenicity of CLP-HAstem. (a) Experimental
setup. Mice (n = 10/group) were immunized thre es with either CLP-HAstem (CLP) or soluble
HAstem (Sol.) at a dose of 1, 5 or 10 µg at 3 week i tervals. On weeks 2, 5 and 8, mice were bled. Four
weeks after the final immunization, mice were challenged intranasally with H1N1 A/Puerto Rico/8/34
(A/PR8) and 5 days post inoculation (p.i) of influenza, mice were euthanized and their lungs harvested.
(b) ELISA measurements of HAstem-specific IgG titres from serum taken at specified weeks. Cut off
was set to OD450nm of 0.2. Each dot represents one animal. Horizontal lines indicate geometric mean
of the group and vertical lines indicate the standard deviation. Significance indicators are shown in
Figure S4. (c) Lung viral titer measured using a MDCK plaque assay. Each dot represents one animal
and horizontal lines represent the median titer per group. Dotted line represents the detection limit of
the assay. * p < 0.05; ** p < 0.005; *** p < 0.0005.
To assess the protective efficacy of the vaccines, mice were challenged with a heterologous H1N1
influenza virus, A/Puerto Rico/8/1934 (H1N1/PR8) 4 weeks after the final immunization. Five days
later, mice were euthanised and the virus burden in the lungs was evaluated in a MDCK plaque assay.
Although anti-HAstem antibody levels were within a similar range between the different vaccination
groups after three immunizations (Figure 2b), significant differences were seen in the virus burden
following the challenge (Figure 2c). Mice vaccinated with the CLP-HAstem vaccine had a significantly
lower viral load compared to the naïve control mice (p < 0.005), irrespective of the antigen dose.
By contrast, only animals vaccinated with the higher doses (5 and 10 µg) of soluble HAstem trimer had
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reduced viral loads compared to the naïve controls. For both the CLP-HAstem and soluble HAstem
vaccine, immunization with 5 or 10 µg antigen resulted in a significantly lower viral load when
compared to the unvaccinated control group (Figure 2c).
3.3. CLP-HAstem Elicits a Long-Lived Protective Response
An important quality of a future universal influenza vaccine is its ability to elicit a long-lasting
protective response to eliminate the need for annual flu shots. With this in mind, the longevity of the
response induced by the CLP-HAstem vaccine was investigated. Mice were immunized with 4.5 µg
antigen in a similar prime-boost-boost schedule as used in the dose-response study and thereafter,
the mice were intermittently bled and HAstem titer followed over a course of 35 weeks (Figure 3a).
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Figure 3. Long-lived protective response i ced by CLP-HAstem. (a) Experimental setup. Mice
(n = 6/group) were im uni thr e times with CLP-HAstem or soluble HAstem at 3 week intervals.
Thiry-four weeks post prime vaccination mice were challenged intranasally with H1N1 Brisbane
A/59/07 (A/Brisbane). Five days post inoculation (p.i) of virus, mice were euthanized and their lungs
harvested. (b) ELISA measurements showing the geometric mean titer (GMT) of total IgG raised against
HAstem plotted against time post imm nization. (c) ELISA measurements of individual anti-HAstem
IgG sub-class titres from serum taken at week 29. Each dot represents one animal. H rizontal lines
indicate the geometric mean of the group and vertical lines indicate the standard deviation. (d) Lung
viral titer was measured using a MDCK plaque assay. Each dot represents one animal. Horizontal lines
represent the median titer per group. Dotted line represents the detection limit of the assay. * p < 0.05;
** p < 0.005.
No difference was observed in the geometric mean titer of anti-HAstem IgG between mice
vaccinated with soluble HAstem trimer or CLP-HAstem (Figure 3b). In both groups, the peak antibody
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titer was observed after the third immunization (measured at week 8). Hereafter, anti-HAstem titers
slowly declined in both vaccination groups between week 9 and week 20, where after the antibody
levels remained at a stable plateau throughout the remainder of the study (measured up to week 29).
The antigen-specific IgG isotype profile, measured 29 weeks after vaccination, revealed that while
both groups had similar amounts of antigen-specific IgG1, mice immunized with CLP-HAstem had a
significantly higher amount of antigen-specific IgG2a (p < 0.005) (Figure 3c).
To assess the protective capacity of the vaccine-induced immune response, mice were challenged
with a homologous influenza strain, H1N1 A/Brisbane/59/2007, 34 weeks after the first vaccination.
Five days after influenza challenge, the lungs were harvested and viral load was measured in a plaque
assay. This experiment showed that whereas both vaccines could reduce the viral load compared to the
unvaccinated control mice, CLP-HAstem vaccinated mice were significantly better protected against
infection (median titer of 7500 PFU/g) compared to mice vaccinated with the soluble HAstem vaccine
(median titer of 500,000 PFU/g); p < 0.005) (Figure 3d).
3.4. A Single Vaccination with CLP-HAstem Protects against Homologous and Heterologous Challenge
To assess the potency of the CLP-HAstem vaccine, the protection induced after a single
immunization was investigated (Figure 4a). Mice were vaccinated once with either soluble HAstem or
the CLP-HAstem at a dose of 4.5 µg HAstem protein. Three weeks after vaccination, mice receiving the
CLP-HAstem vaccine had significantly higher anti-HAstem IgG titers compared to mice receiving the
soluble antigen (p < 0.0005) (Figure 4b). Moreover, as in the previous experiment, mice immunized with
the CLP-HAstem vaccine had significantly higher levels of anti-HAstem IgG2a antibodies (p < 0.0005),
while the IgG1 antibody titer was comparable to mice vaccinated with soluble HAstem (Figure 4c).
Five weeks post-immunization, mice were challenged with either the homologous (A/Brisbane) or
heterologous (A/PR8) influenza virus, and lung viral load was determined in a MDCK plaque assay
3 and 5 days post-inoculation. Mice vaccinated with a single dose of CLP-HAstem were protected
against both viral strains (Figure 4d–g). These mice had a lower viral load in the lungs compared to
unvaccinated mice (median titer 5 days post challenge of 3 × 103 versus 1 × 106 PFU/g (p < 0.005) and
2.5 × 104 versus 1.9 × 107 PFU/g (p < 0.005)) for homologous and heterologous challenge respectively.
Moreover, the mean viral load in the lungs did not increase between days 3 and 5, indicating
that CLP-HAstem vaccination did not simply delay viral replication but rather protected against it
(Figure 4d,e). Finally, CLP-HAstem vaccinated mice showed no weight loss as a result of the either
influenza challenge (Figure 4f,g). Mice vaccinated with the soluble HAstem fared less well. Five days
after homologous challenge, the mean lung viral burden was lower on day 5 compared to the control
animals (p < 0.05), but there was no sign of protection against heterologous challenge, where virus
burden and weight loss were similar to that observed in the unvaccinated control mice (Figure 4d–g).
These results showed that a single dose of the CLP-HAstem vaccine provided protection against
both homologous and heterologous influenza virus challenge in mice and that this vaccine outperformed
a vaccine based on the soluble HAstem trimer.
Figure 4. Cont.
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Figure 4. Single immunization protects against homologous and heterologous influenza challenge.
(a) Experimental setup. Mice (n = 10/group) were immunized with CLP-HAstem or Soluble HAstem
once. Blood was drawn at week 3. Five weeks post vaccination, mice were challenged intranasally
with homologous (A/Brisbane) or heterologous (A/PR8) viral strains. Lungs were harvested on day
3 (n = 5/group) or 5 (n = 5/group) post influenza inoculation (p.i). (b) Anti-HAstem endpoint IgG
titer was measured by ELISA 3 weeks post immunization. (c) ELISA measurements of individual
anti-HAstem IgG isotype titers from serum taken at week 3. Each dot represents one animal. Horizontal
lines indicate geometric mean of the group and vertical lines indicate the standard deviation (n = 10).
(d) and (e) Lungs were isolated 3 or 5 days post challenge with A/Brisbane or A/PR8 respectively and
viral titer was measured using MDCK plaque assay. Each dot represents one animal. Horizontal lines
represent the median titer per group and the dotted line represents the detection limit of the assay.
(f,g) Percentage weight loss following A/Brisbane and A/PR8 challenge respectively. Dots represent
mean, and error bars represent standard deviation. * represents significant differences between the
CLP-HAstem group and the soluble HAstem group. # represents significant differences between the
CLP-HAstem group and naïve controls. * p < 0.05; ** p < 0.005; *** p < 0.0005.
4. Discussion
An effective UFV offering protection against both seasonal and pandemic viral strains would
greatly improve our position in the ongoing battle against influenza. While several antigen candidates
with broadly neutralizing potential (e.g., HA-stem) have been identified [10–14,38,39], several hurdles
to UFV development still need to be overcome. Firstly, while high anti-HA antibody levels are
important for protection [20], it has so far been challenging to induce strong humoral responses against
the conserved stem region. Additionally, the people in society that are most at risk of severe disease and
death, such as the elderly, often have reduced immune responsiveness making successful vaccination
a challenge [40]. Importantly, during pandemic situations, additional requirements such as rapidly
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induced protection (ideally after a single vaccination) and the possibility for dose sparing are also
vital [41]. On this basis, an effective vaccine formulation and delivery platform that can facilitate a fast,
strong and long-lasting immune response is essential for an effective UFV.
It is well documented that presentation of foreign antigens on the surface of a CLP in a repetitive
and ordered format, mimicking that of a native pathogen, can greatly enhance the immune response
elicited against the antigen [26,42]. In this study, we set out to test whether CLP presentation could
increase the immunogenicity and protective efficacy of a promising HAstem vaccine candidate. As a
starting point, we used a HAstem recombinant protein previously engineered to form stable trimers,
exhibiting structural properties comparable to that of the full-length HA, and which has been validated
to induce broad protection, even against heterosubtypic influenza strains [11].
For many viruses, such as HIV, coronaviruses and influenza, the immunologically important
antigens exist as trimers. Therefore, in the context of developing effective vaccines, it is often essential
to deliver the vaccine antigen in a quaternary structure similar to that of the native protein to ensure
that important inter-subunit epitopes are displayed. However, display of multimeric antigens on
CLPs through conventional means has long been technically challenging. Recently however, the
Tag/Catcher AP205 platform was shown to facilitate the display of the large trimeric HIV envelope
antigen [27]. In accordance, the present study has demonstrated the ability of the Tag/Catcher AP205
platform to facilitate high density, repetitive presentation of the HAstem trimer in a unidirectional
manner, while maintaining the accessibility of known bnAb epitopes. Additionally, the observed
anchoring of multiple protomers in each HAstem trimer to the CLP surface may help stabilize the native
structure, thus potentially negating the need for complex engineering of the antigen, which can lead to
the formation of unwanted neoepitopes.
Following the successful development of the CLP-HAstem vaccine, we set out to assess whether
CLP-display could improve the HAstem antigen’s capacity for inducing a protective immune response
in mice. This was done by running multiple immunization/challenge studies comparing head-to-head
a CLP-HAstem vaccine with a similar vaccine containing the soluble HAstem protein. Collectively, the
results indicate that CLP display leads to increased immunogenicity of the HAstem antigen and mediate
a faster induction of protective immune responses. The results also suggest that CLP-display even at
low doses (i.e., 1 ug HAstem antigen) elicits immune responses that lower the lung burden of virus
after heterologous influenza challenge. It is also noteworthy that a single dose of CLP-HAstem vaccine
was sufficient to protect mice against heterologous influenza challenge. Although sterilizing immunity
was not achieved, the vaccination resulted in a significantly lower viral load compared to vaccination
with the soluble HAstem. The results are encouraging in the context of any viral pandemic situation,
where rapidly induced protection from severe disease is required without the necessity for subsequent
booster vaccinations. Equally important, the increased immunogenicity provides the prospect of dose
sparing. The longevity study, which showed that elderly mice that had received the CLP-HAstem were
significantly better protected than mice receiving the benchmarking soluble vaccine, which further
demonstrates the capability of the vaccine to induce long-lived protective responses.
Previous studies assessing soluble HAstem vaccines have reported that while their stem-directed
antibodies provide some protection against morbidity and mortality, the mode of action does not seem
to be related to inhibition of viral replication or decreased viral loads [10,11]. In our study, however,
immunization with CLP-HAstem led to a significant reduction in viral titer compared to naive controls.
This suggests that CLP display is modulating the immune response against the HAstem in a different
direction compared to conventional soluble vaccination.
Although the soluble and CLP-based vaccines induce similar overall antigen-specific antibody
titers after a prime-boost-boost regimen, vaccination with CLP-HAstem resulted in significantly lower
viral loads compared to the soluble HAstem, following influenza challenge. This indicates that the
quality of the humoral response and not the magnitude of the response was critical to the induced
protection. This phenomenon has previously been observed [43–45] and could be due to several factors
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including (i) antibody specificity; (ii) antibody avidity; (iii) IgG subclass switching; and (iv) activation
and synergy with other arms of the immune response including innate immunity and T cell responses.
An increasing body of evidence suggests that the in vivo protection induced by HA-stem-directed
antibodies is largely mediated by antibody-dependent cellular cytotoxicity (ADCC) and is highly
reliant on Fc-FcγR interactions [12,17,18,46]. Therefore, due to their relative affinities for activating
versus inhibitory FcγRs and thus their different effector capabilities, IgG subclass plays a crucial role in
influenza vaccine efficacy. In this study, while soluble vs. CLP display of the trimer did not result
in a different total IgG titer after three immunizations, there was a clear difference in the IgG isotype
profiles between the two groups, with the CLP-HAstem vaccine inducing a significantly higher IgG2a
titre. This isotype switching is likely due to the presence of prokaryotic RNA in the center of the
CLPs, which is passively encapsulated during CLP expression. This RNA acts as a potent TLR7/TLR8
agonist and has been directly linked to increased IgG2a levels in other CLP-based vaccines [19,44,47].
In previous direct head-to-head studies, IgG2a monoclonal antibodies targeting the HA-stem [46] and
M2e antigen [48] have been shown to induce a much more potent protection against lethal influenza
challenge compared to IgG1 antibodies with the same epitope specificity. Thus, literature provides
strong support for the role of IgG2a titer in CLP-HAstem-induced protection. However, more studies,
possibly involving passive antibody transfer or the use of FcγR deficient mice, will be necessary to
fully explore this hypothesis.
In combination with isotype switching, epitope specificity could also be contributing to the
increased efficacy of CLP-HAstem. The unidirectional display facilitated by the tag/catcher conjugation
strategy has previously shown to enable a more focused humoral response by masking certain regions
of the antigen and promoting the accessibility or dominance of others [27]. While not directly evaluated
in this study, the antibody repertoire induced by CLP-HAstem may be focused on the more functionally
relevant and vulnerable regions of the stem trimer, resulting in increased protection from viral challenge.
Conversely, HAstem in its soluble formulation may have induced antibodies predominantly targeting
non-protective sites of the antigen, including the neoepitopes engineered into the trimer during its
design. Detailed epitope mapping [49] of the antibody pools induced by each vaccine could reveal if
this is indeed the case.
5. Conclusions
CLP display of the HAstem trimer resulted in a potent, rapidly induced and long-lasting protective
response against influenza challenge in mice; properties that would be of essential importance in a
pandemic situation. Although further studies will be needed to fully reveal the mechanism underlying
this enhanced efficacy, our results show that CLP-HAstem is a promising universal flu vaccine candidate
and supports the use of the Tag/Catcher AP205 platform in the development of vaccines targeting other
trimeric viral antigens.
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